

DISTRIBUTION AGREEMENT SECURED FOR U.S. FEDERAL HEALTHCARE FACILITIES

Highlights:

- *Distribution Agreement secured with MellingMedical LLC to promote and sell Osteopore products within healthcare facilities owned or operated by the United States federal government.*
- *MellingMedical has access to more than 165 Veteran's Affairs (VA) Medical Centers, 300 VA Outpatient Clinics, and 95 Department of Defense Medical Facilities.*
- *MellingMedical will market and sell Osteopore's FDA-cleared products to Veteran's Affairs and Department of Defense facilities that have neuro and trauma surgery capabilities.*
- *Osteopore's U.S. distributor, Bioplate Inc, will be appointing sales representatives to work exclusively with MellingMedical to promote Osteopore products across their network.*

3 August 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce its U.S. based distributor Bioplate Inc, has secured a non-exclusive Distribution Agreement ("the Agreement") with MellingMedical LLC to promote and sell Osteopore products within healthcare facilities owned or operated by the United States federal government.

MellingMedical offers federal health care agencies a full array of healthcare products, with a focus on providing military veterans better access to quality and cost-effective medical equipment, supplies and pharmaceuticals. MellingMedical has access to more than 165 Veteran's Affairs (VA) Medical Centers, 300 VA Outpatient Clinics, all 7 Consolidated Mail Outpatient Pharmacies, and 95 Department of Defense Medical Facilities.

Under the terms of the Agreement, MellingMedical will market and sell Osteopore's FDA-cleared products to healthcare facilities owned or operated by the United States federal government, both domestically and internationally. The initial focus will be supplying products to Veteran's Affairs and Department of Defense facilities that have neuro and trauma surgery capabilities.

Osteopore Executive Chairman, Mark Leong said, "This is an important and progressive milestone in the execution of our strategy of extending our presence in a key market like the USA. Working closely with MellingMedical, we now have inroads to their wide and

considerable access to VA related medical facilities and clinics throughout USA and helps extend the footprint of our products. We are all enthused with this latest development and credit the team for imprinting Osteopore as a viable solution in the USA cranial market.”

Bioplate CEO, Thomas Hopson, said, “We are excited about this agreement because it allows the VA, military hospitals, and other government facilities an opportunity to have access this novel technology. The Osteopore products address a clinical need that has not been solved with traditional cranial closure products.”

Founder and CEO of MellingMedical, Chris Melling, said, “We are amazed at the efficacy of Osteopore’s solutions and their ability to enhance and accelerate the body’s natural regenerative processes. Their technology’s potential to improve the quality of life for patients recovering from injury or even congenital skeletal defects is a game changer.”

Next Steps

Bioplate and Osteopore will work with MellingMedical to apply for listing in the Federal Supplies Schedule (FSS). Upon successful listing confirmation, anticipated within six (6) months, Osteopore products will be available to all federal healthcare facilities. Bioplate will appoint sales representatives to exclusively work with MellingMedical to promote Osteopore products across their network.

Osteopore and Bioplate will also work closely with MellingMedical, to train and support Bioplate’s sales representatives to facilitate ongoing promotion at targeted neuro-trauma centers across federal healthcare facilities.

Additional Agreement Details

This Agreement signed between Bioplate and MellingMedical effective 1 August 2022, shall be for a term of one year (“Initial Term”) and shall continue on a year-to-year basis thereafter (“Additional Term”). The terms of the Agreement do not contain binding minimum sales thresholds. Each party will bears their own costs. Either Party may terminate the Agreement as of the end of the Initial Term or any Additional Term by providing thirty (30) days written notice thereof to the other Party. The termination or expiration of this Agreement shall not affect either Party’s obligations to the other Party under any orders submitted by MellingMedical and accepted by Bioplate prior to such expiration or termination. The Agreement also contains such other terms that are standard in commercial distribution agreements of this type.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

About Melling Medical

Melling Medical, a CVE-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), holds a Medical Equipment and Surgical Federal Supply Schedule (Med/Surg), as well as a Pharmaceutical Schedule, and currently serves more than 165 VA Medical Centres and 300 VA Outpatient clinics, all seven (7) VA CMOPs, 95 DoD Medical Facilities and Health and Human Services (HHS), including Indian Health Services (IHS) and the Center for Disease Control (CDC). Melling Medical provides access to innovative and cost-effective healthcare solutions in ophthalmology, optometry, urology, and pharmaceuticals.

About Bioplate

Bioplate designs and manufactures cranial closure and bone fixation systems for neurosurgery. The company was founded in 1995 and continues to share the founders' commitment to patient safety and practitioners' insight into the needs of the operating room. A focus on safety and effectiveness remains at the core of the company's philosophy. With two decades of experience in product innovation and sales, they have built a reputation around high quality precision products and superior service. Bioplate is a privately held corporation based in Los Angeles, CA.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.